PD-L1 in Combination with CD8+TIL and HIF-1α are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma
Zihan Zhou,1,2 Dianbin Mu,3 Dexian Zhang,3 Xianbin Zhang,2 Xingchen Ding,2 Jia Yang,2 Xinbin Bai,4 Man Hu2 1Department of Oncology, Weifang Medical University, Weifang, Shandong, People’s Republic of China; 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong...
Main Authors: | Zhou Z, Mu D, Zhang D, Zhang X, Ding X, Yang J, Bai X, Hu M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-12-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/pd-l1-in-combination-with-cd8til-and-hif-1alpha-are-promising-prognosi-peer-reviewed-article-CMAR |
Similar Items
-
PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection
by: Fan Yang, et al.
Published: (2018-12-01) -
The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
by: Lu Chen, et al.
Published: (2019-12-01) -
Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
by: Juan L. Callejas-Valera, et al.
Published: (2022-05-01) -
Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
by: Siqing Jiang, et al.
Published: (2022-09-01) -
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
by: Alessio Cirillo, et al.
Published: (2024-04-01)